Relationship of complement activation route with clinical manifestations in Japanese @entity1 with XXXX : A retrospective observational study.

@entity1 @entity19509 @entity1310 @entity625 @entity1252 @entity1701 @entity11534
Objectives. To assess the relationship between the complement activation route and clinical manifestations in @entity1252 ( @entity1252 ). Methods. @entity1 with @entity1252 in whom complement activation occurred were divided into two groups: those in whom the complement system was mainly activated through the classical pathway (low serum @entity19509 levels; CP group); and those in whom the complement system was solely activated through the alternative pathway (low serum C3 with normal C4 levels; AP group). Clinical manifestations were compared between the groups. Results. The CP group had higher frequencies of @entity625 , @entity11534 , and @entity1310 , and a higher prevalence of anti-DNA antibodies compared to the AP group ( @entity625 : 50.0% vs. 13.0%, p = 0.0014; @entity11534 : 37.5% vs. 13.0%, p = 0.0257; @entity1310 : 63.6% vs. 21.7%, p = 0.0003; anti-DNA antibodies: 73.9% vs. 30.4%, p = 0.0001). In contrast, the AP group had a higher frequency of anti-phospholipid (anti-PL) antibodies and a higher prevalence of @entity1701 ( @entity1701 ) (anti-PL antibodies: 70.6% vs. 37.3%, p = 0.0136; @entity1701 : 39.1% vs. 5.7%, p < 0.0001). Conclusions. Our results suggest that a different complement system mechanism may act in the pathogenesis of @entity1701 in @entity1 with @entity1252 .
